1-(5-tert-butyl-2-phenyl-2h-pyrazol-3yl)-3-[2-fluoro4-(1-methyl-2-oxo-2,3dihydro-1h-imidazo [4,5-b]pyridin-7yloxy)-phenyl] -urea and related compounds and their use in therapy

Details for Australian Patent Application No. 2011209586 (hide)

Owner Institute of Cancer Research: Royal Cancer Hospital (The) Cancer Research Technology Limited

Inventors Springer, Caroline; Niculescu-Duvaz, Ion; Marais, Richard; Niculescu-Duvaz, Dan; Zambon, Alfonso; Menard, Delphine

Agent FB Rice

Pub. Number AU-A-2011209586

PCT Pub. Number WO2011/092469

Priority 61/300,085 01.02.10 US

Filing date 27 January 2011

Wipo publication date 4 August 2011

International Classifications

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/437

A61P 35/00 Antineoplastic agents

Event Publications

9 August 2012 PCT application entered the National Phase

  PCT publication WO2011/092469 Priority application(s): WO2011/092469

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011209591-Memory power reduction in a sleep state

2011209584-Process for preparing and purifying fatty acids